More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Oncology is a complex and rapidly-evolving management challenge for payers.
Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.
A number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
FDA’s approval of the first generic version of Copaxone for treating patients with relapsing forms of multiple sclerosis has industry insiders contemplating the impact on the generics market as well as payer coverage strategies.
Consensus is building on the promise of genetic testing and other technological advances to help individualize testing, prevention and treatment for better outcomes.